PARP Inhibitor Biomarkers

Global PARP Inhibitor Biomarkers Market to Reach US$1.5 Billion by 2030

The global market for PARP Inhibitor Biomarkers estimated at US$951.7 Million in the year 2024, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 7.6% over the analysis period 2024-2030. PARP Inhibitor Biomarker Kits, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$1.0 Billion by the end of the analysis period. Growth in the PARP Inhibitor Biomarker Assays segment is estimated at 5.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$259.3 Million While China is Forecast to Grow at 12.1% CAGR

The PARP Inhibitor Biomarkers market in the U.S. is estimated at US$259.3 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$317.4 Million by the year 2030 trailing a CAGR of 12.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.7% and 7.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.

Global PARP Inhibitor Biomarkers Market – Key Trends & Drivers Summarized

Why Is the PARP Inhibitor Biomarkers Market Gaining Momentum?

The PARP inhibitor biomarkers market is expanding as the role of precision medicine in oncology continues to grow. PARP (poly ADP-ribose polymerase) inhibitors are a class of targeted therapies used in the treatment of cancers such as ovarian, breast, prostate, and pancreatic cancer. The need for predictive biomarkers to identify patients who will respond to PARP inhibitors is driving advancements in companion diagnostics and genomic testing.

Additionally, the increasing availability of next-generation sequencing (NGS) and liquid biopsy technologies is enabling more precise biomarker identification, improving treatment selection and patient outcomes. The expansion of clinical trials exploring new applications of PARP inhibitors is further fueling market demand.

How Are Genomic Testing and Companion Diagnostics Transforming PARP Inhibitor Biomarker Identification?

The integration of genomic testing into cancer care is revolutionizing PARP inhibitor biomarker discovery. BRCA1/2 mutation testing, homologous recombination deficiency (HRD) assays, and loss-of-heterozygosity (LOH) analysis are becoming standard tests for predicting PARP inhibitor efficacy. These biomarkers help oncologists tailor treatment plans, improving therapeutic success rates.

Companion diagnostics are also playing a crucial role, with regulatory agencies approving biomarker-based tests alongside PARP inhibitor therapies. AI-driven bioinformatics tools are further refining biomarker identification, enhancing accuracy and clinical decision-making.

Is the Expansion of PARP Inhibitor Applications Driving Market Growth?

The growing application of PARP inhibitors beyond ovarian and breast cancer is expanding the market for PARP inhibitor biomarkers. Research is exploring their use in lung, pancreatic, and colorectal cancers, increasing the demand for biomarker testing to guide patient selection.

Additionally, the rise of combination therapies involving PARP inhibitors and immune checkpoint inhibitors is driving biomarker innovation. Scientists are developing predictive tests that assess tumor microenvironments and immune response, leading to more personalized treatment strategies.

What’s Driving the Growth of the PARP Inhibitor Biomarkers Market?

The growth in the PARP inhibitor biomarkers market is driven by the increasing adoption of precision oncology, advancements in genomic testing, and the expansion of PARP inhibitor applications. The rising demand for companion diagnostics and AI-powered biomarker identification is further accelerating market growth.

Additionally, regulatory approvals for biomarker-driven therapies, the growing investment in cancer research, and the integration of NGS and liquid biopsy technologies are fueling innovation. As personalized cancer treatment continues to evolve, the demand for PARP inhibitor biomarkers is expected to rise significantly.

SCOPE OF STUDY:

The report analyzes the PARP Inhibitor Biomarkers market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product Type (PARP Inhibitor Biomarker Kits, PARP Inhibitor Biomarker Assays); Application (Breast Cancer Application, Ovarian Cancer Application, Other Applications)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• Agilent Technologies, Inc.
• Ambry Genetics
• Amoy Diagnostics Co., Ltd.
• AstraZeneca
• Bio-Rad Laboratories, Inc.
• CENTOGENE N.V.
• Exagen Inc.
• F. Hoffmann-La Roche AG
• Genway Biotech, Inc.
• GlaxoSmithKline (GSK)
• Illumina, Inc.
• Invitae Corporation
• Merck & Co., Inc.
• Myriad Genetics, Inc.
• NeoGenomics Laboratories
• Pfizer Inc.
• QIAGEN
• Siemens Healthcare GmbH
• Svar Life Science AB
• Thermo Fisher Scientific Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.